ClinicalTrials.gov
ClinicalTrials.gov Menu

ATAC - Arimidex, Tamoxifen Alone or in Combination

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00849030
Recruitment Status : Completed
First Posted : February 23, 2009
Last Update Posted : June 6, 2012
Sponsor:
Information provided by (Responsible Party):
AstraZeneca

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The aim of this study is to test whether Arimidex alone or in combination with Tamoxifen is beneficial in the treatment of breast cancer.

Condition or disease Intervention/treatment Phase
Breast Cancer Drug: Anastozole (Arimidex) Drug: Tamoxifen (Nolvadex) Drug: Anastozole (Arimidex) placebo Drug: Tamoxifen (Nolvadex) placebo Phase 3

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 9358 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomised, Double Blind Trial Comparing Arimidex Alone With Nolvadex Alone With Arimidex and Nolvadex in Combination, as Adjuvant Treatment in Post-Menopausal Women With Breast Cancer
Study Start Date : July 1996
Actual Primary Completion Date : June 2001
Actual Study Completion Date : April 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Active Comparator: 1
Arimidex 1mg + Nolvadex placebo
 Drug: Anastozole (Arimidex)
1mg, orally, once daily
Other Name: Arimidex

Drug: Tamoxifen (Nolvadex) placebo
20mg, orally, once daily
Active Comparator: 2
Arimidex placebo + Nolvadex 20mg
 Drug: Tamoxifen (Nolvadex)
20mg, orally, once daily
Other Name: Nolvadex

Drug: Anastozole (Arimidex) placebo
1mg, orally, once daily
Active Comparator: 3
Arimidex 1mg + Nolvadex 20mg
 Drug: Anastozole (Arimidex)
1mg, orally, once daily
Other Name: Arimidex

Drug: Tamoxifen (Nolvadex)
20mg, orally, once daily
Other Name: Nolvadex


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Time to recurrence of breast cancer [ Time Frame: Earliest of local or distant recurrence, new primary breast cancer, or death ]
  2. Safety and side effects [ Time Frame: Earliest of local or distant recurrence, new primary breast cancer, or death ]

Secondary Outcome Measures :
  1. Time to distant recurrence [ Time Frame: Earliest of local or distant recurrence, new primary breast cancer, or death ]
  2. Survival [ Time Frame: Earliest of local or distant recurrence, new primary breast cancer, or death ]
  3. New breast primaries [ Time Frame: Earliest of local or distant recurrence, new primary breast cancer, or death ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   45 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with histologically proven operable invasive breast cancer
  • Patients who have completed all primary surgery and chemotherapy (if given), and are candidates to receive hormonal adjuvant therapy
  • Women defined as post-menopausal

Exclusion Criteria:

  • Patients in whom there is any clinical evidence of metastatic disease
  • Patients who, for whatever reason (e.g. confusion, infirmity, alcoholism), are unlikely to comply with trial requirements
  • Patients whose chemotherapy was started more than 8 weeks (ie 56 days) after completion of primary surgery or whose chemotherapy was completed more than 8 weeks (ie 56 days) before starting randomised treatment
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

No Contacts or Locations Provided
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT00849030     History of Changes
Other Study ID Numbers: 1033IL/0029
D5392C00029
First Posted: February 23, 2009    Key Record Dates
Last Update Posted: June 6, 2012
Last Verified: June 2012

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Tamoxifen
Anastrozole
Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
 Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Selective Estrogen Receptor Modulators
Estrogen Receptor Modulators
Bone Density Conservation Agents
Aromatase Inhibitors
Steroid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action